Feb 18, 2021 8:36am
Cognate s buyout-to-be comes shortly after the company plotted cell and gene therapy manufacturing expansions in Europe and the U.S. (Cognate BioServices)
Just a few weeks after Cognate BioServices moved to beef up its cell and gene therapy manufacturing, the company has attracted a buyer eager to tap that expertise.
Charles River Laboratories agreed to throw down $875 million cash for Cognate in a deal designed to create a one-stop-shop in cell and gene therapies. Cognate s production muscle will complement Charles River s own work in the field to bring development, testing and manufacturing under one umbrella, the companies said Wednesday.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
First National Corporation to Acquire The Bank of Fincastle
First National CorporationFebruary 18, 2021 GMT
STRASBURG, Va. and FINCASTLE, Va., Feb. 18, 2021 (GLOBE NEWSWIRE) First National Corporation (the “Company” or “First National”) (NASDAQ: FXNC), the bank holding company of First Bank ( “First Bank”) and The Bank of Fincastle (“Fincastle”) (OTCPK: BFTL) jointly announced today the signing of a definitive merger agreement.
Upon completion of the acquisition, the combined company is expected to have approximately $1.2 billion in assets, $868 million in loans, $1.0 billion in deposits and 20 branch offices across Virginia. First National expects the transaction to be approximately 10% accretive to earnings per share.